Harvard's interim president should quit boards of two drug companies

As a director at a for-profit company, he has a fiduciary responsibility to advocate for the growth, profits, and shareholders of that company. Given the turmoil at Harvard, how can this conflict of interest not be disqualifying?

Related Keywords

Elizabeth Koh , Daniel Kool , Alanm Garber , Vertex Pharmaceuticals , Exelixis Inc , Harvard University , ,